Agent for pig hepatosis prevention

FIELD: medicine.

SUBSTANCE: invention refers to veterinary science, namely to therapy of internal non-transmitting diseases, particularly to drugs for pig hepatosis prevention. The agent for pig hepatosis prevention contains the ingredients in the following relation: antihepatotoxic serum 0.9-1.15 titre units; antisplenotoxic serum 0.9-1.15 titre units; leukocyte plasma 90-110 embryo units; phenol 0.004-0.005 mg; physiologic saline up to 1 ml.

EFFECT: invention allows higher effectiveness of pig hepatosis prevention.

4 tbl

 

The invention relates to veterinary medicine and can be used for the prevention of laboratory pigs.

It is known tool for the prevention of hepatosis in pigs as 0,037%solution of sodium hypochlorite, which is injected intraperitoneally at a dose of 5 ml/kg of body weight. (1)

The use of this tool requires the preparation of sodium hypochlorite using a special device - the electrolyzer, which greatly complicates and increases the cost of prevention.

Known means of prevention hepatosis in pigs in the form of sorbent SV-1, which is introduced to the diet daily for 9 days at a dose of 1.5 g/bird. (2)

The disadvantage of this tool is the necessity of daily add it to food, which increases the cost of production.

It is known tool for the prevention of laboratory pigs - Lipemic - amide 6,8-cityoklahoma acid. As an active metabolite he has a hepatotropic, detoxifying and choleretic action, increases diuresis, stimulates the growth of animals.

The drug piglets (age 2.5-3 months) given to food for 28 days at a dose of 5 mg/kg of body weight.

It was found that pigs with clinical signs hepatosis receiving lipemic already on the 6-7th day disappear signs of diarrhoea, improves appetite. Clinically and in terms of the physiological state of the animals were healthy, the s. Average daily weight gain of pigs was 437, (5)

The disadvantage of this tool is the necessity of daily add it to food and possible complications after application.

Known means of prevention hepatosis in pigs: dapremont with vitamin C, vitamin U, and s (METAVIR) and vitamins U and E (tomsovic). Drugs are as follows: diplomant and vitamin C in the ratio 1:1 with 15-20 th to 60-65-St days of life at a dose of 20 mg/kg of body weight, metavit in the ratio of 1:1 at a dose of 0.2 ml/kg of body weight and tomsovic in the ratio of 1:0.5 in the dose of 1 ml/kg of body weight. Cases steatosis experimental animals were observed. (6)

The disadvantage of these complex tools is their high cost and the possibility of overdose in the application.

Known means of prevention hepatosis in pigs - sodium Selenite. In households where marked by mass disease steatosis, prophylactic treatment of sodium Selenite should be conducted twice. First time at the age of 5-7 days, the second 30-day dose of 0.1-0.2 ml of 0.1%solution of 1 kg of body weight.

Where from hepatosis piglets die at an early age, the drug is administered to pregnant sows once in 20-25 days before farrowing rate of 1 ml per 10 kg of body weight. The piglets born from sows, sodium Selenite injected once in 10 days of age. (4)

Weeks the STATCOM this tool is its high toxicity in overdose and possible mass mortality of pigs.

It is known tool for the prevention of laboratory pigs antihepatotoxic serum. The use of small doses of serum (0,2 unit) once subcutaneously or intramuscularly allows to normalize disturbed as a result of the pathological process of the functional state of the liver. (3)

The advantage of this tool is single use and low cost.

This tool is closest to the technical essence and selected for the prototype, has the following disadvantage: for effective action antihepatotoxic serum it is necessary to determine the immune status of the population and depending on it to adjust the dose antihepatotoxic serum.

The aim of the invention is to develop means of prevention hepatosis in pigs, allows prevent liver disease and stimulate the organs of the immune system. This objective is achieved in that in addition to antihepatotoxic serum is added antiperoxidase serum and leukocyte plasma to enhance the effect antihepatotoxic serum and increase the natural resistance of the body, which is very important when steatosis.

The remedy for the prevention of laboratory pigs is a clear pink liquid with a slight precipitate, easily broken when JAC is jivani. 1 ml of the preparation contains from 0.9-1,15 tetrofosmin units antihepatotoxic and antiperoxidase sera for binding assays of complement and leukocyte plasma with actinistia 90-110 embryonic units of activity per 1 ml (EEA/ml), phenol - 0,004-0,005 mg

The drug must be sterile, non-toxic and pyrogen-free.

The shelf life when stored at the temperature +5 - +7C 2 years.

The proposed scheme of obtaining funds for the prevention of laboratory pigs consists of the following steps:

1. Obtaining antigen from the liver. For preparation of antigen from the liver to use the liver of healthy pigs. Pieces of liver 4-6 times washed from the blood of 10-fold volume of isotonic sodium chloride solution. The pieces are crushed, pounded in a mortar with glass and throw a 0.85% solution of sodium chloride to 10%concentration. The resulting suspension is centrifuged 9-10 minutes at 2500-3000 rpm and as antigen use the supernatant liquid. Antigen lighten five times freezing and thawing, followed by centrifugation at 7000-8000 rpm for 9-10 minutes. Keep the antigen in frozen state.

2. Obtaining antigen from the spleen. For preparation of antigen from the spleen using the spleen of healthy pigs. Pieces spleen 4-6 times washed from the blood of 10-fold volume of isotonic dissolve the sodium chloride. The pieces are crushed, pounded in a mortar with glass and throw a 0.85% solution of sodium chloride to 10%concentration. The resulting suspension is centrifuged 9-10 minutes at 2500-3000 rpm and as antigen use the supernatant liquid. Antigen lighten five times freezing and thawing, followed by centrifugation at 7000-8000 rpm for 9-10 minutes. Keep the antigen in frozen state.

3. The choice of the donor animals. For the preparation of products for the prevention of laboratory pigs as donors suitable for the following species: horses, rabbits, cattle and small cattle. Donors must be free from infectious diseases and undergo quarantine.

4. Getting antihepatotoxic serum. Antihepatotoxic serum produced by hyperimmunization donors under the scheme: the first injection of antigen is performed subcutaneously in the region of the left scapula and right popliteal fossa; the second introduction after 6-8 days subcutaneously in the right shoulder blade and the left popliteal fossa; the third injection is carried out through the same period as second - intravenously and subcutaneously in the above point. After 6-8 days after the third injection of the antigen test blood sampling and determine the titer obtained antihepatotoxic serum in the reaction of complement fixation. If there titer of at least 1:160-1:20 conduct blood sampling. The resulting blood is placed in a thermostat at 29-30 minutes at 36-37C, then under sterile conditions to separate the clot from the wall and leave the tube in the refrigerator for better retraction of the clot until the next day. The resulting serum is sucked off and canned phenol 0.5%concentration of the substance in the serum.

5. Getting antiperoxidase serum. Antiperoxidase serum produced by hyperimmunization donors under the scheme: the first injection of antigen is performed subcutaneously in the region of the left scapula and right popliteal fossa; the second introduction after 6-8 days subcutaneously in the right shoulder blade and the left popliteal fossa; the third injection is carried out through the same period as second - intravenously and subcutaneously in the above point. After 6-8 days after the third injection of the antigen test blood sampling and determine the titer obtained antiperoxidase serum in the reaction of complement fixation. If there titer of at least 1:160-1:200 conduct blood sampling. The resulting blood is placed in a thermostat at 29-30 minutes at 36-37C, then under sterile conditions to separate the clot from the wall and leave the tube in the refrigerator for better retraction of the clot until the next day. The resulting serum is sucked off and canned phenol 0.5%concentration of the substance in the serum.

6. Obtaining leukocyte plasma is s. From healthy pigs weighing 100-110 kg at slaughter collect blood in sterile glass liter cylinders, pre-add 100 ml of 2%aqueous solution of the trylon B.

To accelerate the sedimentation of erythrocytes to blood add 70 ml of 5%aqueous solution of polyvinyl alcohol, gently mix and defend the mixture for one hour.

After erythrocyte sedimentation plasma suspended in it by leukocytes is sucked off and poured into a sterile flask, add much to eliminate possible bacterial contamination 150-200 IU of penicillin and streptomycin, 1 ml of plasma. When this plasma should contain from 16 to 20 thousand cells in 1 ml

Bulb with a suspension of cells in plasma is placed in a thermostat and incubated at a temperature of 38-39C for 48-72 hours.

Then incubated plasma centrifuged at about 2.5-3.0 Tyson/min for 20 minutes and check the activity on developing a 10-day-old chick embryos. Plasma activity in embryonic units of activity should be at least 90-110 AEA/ml

7. Receiving means for the prevention of laboratory pigs. To obtain funds for the prevention of laboratory pigs antihepatotoxic, antiperoxidase serum and leukocyte plasma is mixed with sterile saline solution, canned phenol 0.5%concentration with such rascheta is, to 1.0 ml was kept for the 0.9-1,15 tetrofosmin units antihepatotoxic and antiperoxidase sera for binding assays of complement and leukocyte plasma activity 90-110 AEA/ml

Comparative analysis of the claimed preparation tool selected for the prototype showed that the means for prevention hepatosis in pigs has the following distinctive features:

- additionally includes antiperoxidase serum in the amount of from 0.9 to 1.15 tetrofosmin units by the reaction of binding of complement and leukocyte plasma activity 90-110 AEA/ml, and antihepatotoxic serum is used with activity from 0.9 to 1.15 tetrofosmin units by the reaction of complement fixation.

The presence of the distinctive features of the prototype characteristics ensures compliance with the proposed technical solution the criterion of "novelty": from the prior art are not aware of biologically active preparations containing simultaneously in 1.0 ml of 0.9-1,15 tetrofosmin units antihepatotoxic and antiperoxidase sera for binding assays of complement and leukocyte plasma activity 90-110 AEA/ml

Tested products for the prevention of laboratory pigs confirm its advantages over drug prototype.

Example: scheme of the receiving means for the prevention hepatosis the pigs.

1. Obtaining antigen from the liver. For preparation of antigen from the liver used the liver of healthy pigs. Pieces of liver 5 times washed from the blood of 10-fold volume of isotonic sodium chloride solution. The pieces were crushed, rubbed in a mortar with glass and bred a 0.85% solution of sodium chloride to 10%concentration. The resulting suspension was centrifuged 10 minutes at 3000 rpm and the quality of the antigen used the supernatant. The antigen was osvetleni five times freezing and thawing, followed by centrifugation at 8000 rpm for 10 minutes. Kept antigen in frozen state.

2. Obtaining antigen from the spleen. For preparation of antigen from the spleen used the spleen of healthy pigs. Pieces spleen 5 times washed from the blood of 10-fold volume of isotonic sodium chloride solution. The pieces were crushed, rubbed in a mortar with glass and bred a 0.85% solution of sodium chloride to 10%concentration. The resulting suspension was centrifuged 10 minutes at 3000 rpm and the quality of the antigen used the supernatant. The antigen was osvetleni five times freezing and thawing, followed by centrifugation at 8000 rpm for 10 minutes. Kept antigen in frozen state.

3. As a donor used healthy rabbits, past the quarantine is the testing.

4. Getting antihepatotoxic serum. Antihepatotoxic serum was obtained by hyperimmunization donors under the scheme: the first injection of antigen was performed subcutaneously in the region of the left scapula and right popliteal fossa in a dose of 40 mg of protein in 1 ml; the second introduction after 7 days subcutaneously in the right shoulder blade and the left popliteal fossa in a dose of 60 mg of protein in 1 ml; the third injection was performed through the same time as the second intravenous dose of 80 mg protein in 1 ml subcutaneously at a dose of 50 mg per 1 ml of the above points. 7 days after the third injection of antigen did test the blood samples and determined the titer obtained antihepatotoxic serum in the reaction of complement fixation. If there titer of at least 1:160-1:200 spent taking blood from a rabbit in a quantity of 50 ml of the Obtained blood was placed in a thermostat at 30 minutes at 37C. then, under sterile conditions separated the clot from the wall and left the tube in the refrigerator for better retraction of the clot until the next day. The resulting serum was aspirated conserved phenol 0.5%concentration of the substance in the serum.

5. Getting antiperoxidase serum. Antiperoxidase serum was obtained by hyperimmunization donors under the scheme: the first injection of antigen was performed subcutaneously in the region of the left scapula and right popliteal fossa to the e 40 mg protein in 1 ml; the second introduction after 7 days subcutaneously in the right shoulder blade and the left popliteal fossa in a dose of 60 mg of protein in 1 ml; the third injection was performed through the same time as the second intravenous dose of 80 mg protein in 1 ml subcutaneously at a dose of 50 mg per 1 ml of the above points. 7 days after the third injection of antigen did test the blood samples and determined the titer obtained antiperoxidase serum in the reaction of complement fixation. If there titer of at least 1:160-1:200 spent taking blood from a rabbit in a quantity of 50 ml of the Obtained blood was placed in a thermostat at 30 minutes at 37C. then, under sterile conditions separated the clot from the wall and left the tube in the refrigerator for better retraction of the clot until the next day. The resulting serum was aspirated and canned phenol 0.5%concentration of the substance in the serum.

6. Obtaining leukocyte plasma. From healthy pigs weighing 100-110 kg at slaughter gathered the blood into a sterile glass liter cylinders, pre-add 100 ml of 2%aqueous solution of the trylon B.

To accelerate the sedimentation of erythrocytes to blood added to 70 ml of 5%aqueous solution of polyvinyl alcohol, gently mixed and defended the mixture for one hour.

After erythrocyte sedimentation plasma weighted in her white cells was aspirated and poured into a sterile flask, where we use the and to remove possible bacterial contamination of 200 IU of penicillin and streptomycin, 1 ml of plasma. When this plasma should contain from 16 to 20 thousand cells in 1 ml

Bulb with a suspension of cells in plasma was placed in a thermostat, and incubated at a temperature of 38.5C for 72 hours.

Then incubated plasma was centrifuged at 3.0 thousand rpm for 20 minutes and checked the activity on developing a 10-day-old chick embryos. Plasma activity in embryonic units of activity should be at least 100 AEA/ml

7. Receiving means for the prevention of laboratory pigs. To obtain funds for the prevention of laboratory pigs antihepatotoxic, antiperoxidase serum and leukocyte plasma was mixed with sterile saline solution, canned phenol 0.5%concentration so that 1.0 ml was kept at 1.0 tetrofosmin units antihepatotoxic and antiperoxidase sera for binding assays of complement and leukocyte plasma with an activity of 100 AEA/ml

To determine the optimal dose prophylaxis hepatosis in pigs was staged experience.

With this purpose, 100 pigs were divided on the principle of steam-analogs in four groups of 25 animals in each group. All pigs were housed under identical conditions of feeding and maintenance.

Piglets of the first group served as control, it is a means to prevent heat is for the pigs did not enter.

The piglets of the second group was administered agent for the prevention of laboratory pigs at a dose of 0.1 ml/kg body weight.

The piglets of the third group was administered agent for the prevention of laboratory pigs at a dose of 0.2 ml/kg body weight.

Pigs fourth group was administered agent for the prevention of laboratory pigs at a dose of 0.4 ml/kg body weight.

Observation of animals was performed within 1 month of taking into account the number of dead pigs and especially the anatomic dissection of corpses.

The results of the experience are reflected in tables 1 and 2.

1. Results determination of optimal dose prophylaxis hepatosis in pigs
GroupThe number of animalsThe dose for the prevention of hepatosis in pigs in ml/kgPaloThe number of the fallen with a diagnosis of steatosis
group 125-11
group 2250,111
group 3250,2--
group 4250,4--

From the table it follows that the optimal doses of means for the prevention of laboratory pigs are the doses of 0.2 and 0.4 ml/kg In these groups the mortality of Guinea pigs was not. While in the first trial (dose 0.1 ml/kg) and control groups fell one pig.

39,80,4**
2. The results of biochemical analysis of blood serum of piglets in the application of different doses of prophylaxis hepatosis in pigs
IndexGroups of animals
group 1group 2group 3group 4
Total protein, g/l73,00,386,02,0*89,00,3**88,01,0*
Albumin, %33,70,236,51,338,80,7*
Alpha-globulins, %14,80,616,70,116,50,116,400,09
Beta-globulins, %12,100,0814,80,2**15,20,2**14,60,2*
Gamma-globulins, %31,90,128,90,2**28,20,6*28,30,7*
The ratio A/G0,50,60,70,6
* - p<0,05, ** - p<0,01

When studying the content of total protein and protein fractions in the serum of experimental animals the increase of total protein content in all experimental groups compared to control. In the first experimental group it was +17.9 percent (p<0,05), while the second +21,9% (p<0.01), and in the third of 20.5% (p<0,05). Also in the experimental groups compared with the control, there was an increase of the content of albumin. Most of their number increased in the second experimental group +18,1% (p<0.01), and in the first experimental group +8.0% in the third group the e - +15,1% (p<0,05). In all experimental groups has been significant increase in the content of beta-globulin from 20.6 per cent to 25.6%. The content in the serum gamma-globulin in the experimental groups decreased compared with the control. The maximum decrease was in the second experimental group 11.6%, in the third group by 11.3% in the first 9.4%. All changes have been reliable. The ratio of albumin to globulins, which determines the functional state of the liver was within the normal range only in piglets second experimental group.

Thus, on the basis of clinical and biochemical studies have established that the optimal and economically viable dose prophylaxis hepatosis in pigs is 0.2 ml/kg

Comparison of the effectiveness of prophylaxis hepatosis in pigs in relation to antihepatotoxic serum was performed in the experience on the Borovka age 30 days, weight 9 kg

With this purpose, 50 pigs were divided on the principle of steam-analogues into two groups of 25 animals in each group. All pigs were housed under identical conditions of feeding and maintenance.

Piglets of the first group served as control, were introduced antihepatotoxic serum in a dose of 0.2 ml/kg content antihepatotoxic serum 1,0 trevojnyh units in 1 ml

The piglets of the second group was administered agent for the prevention of hepatitis is and pigs at a dose of 0.2 ml per 1 kg of live weight.

Observation of animals was performed within 1 month of taking into account the number of dead pigs and especially the anatomic dissection of corpses.

The results of the experience are reflected in tables 3 and 4.

3. Impact means for the prevention of laboratory pigs and antihepatotoxic serum on safety and prevention hepatosis in pigs
GroupThe number of animalsPaloDiagnosis at autopsy
group 12533 heads - steatosis
group 22511 head gastroenteritis

From the table it is seen that during the observation period in the control group safety was 88%, while the cause of these deaths in the control group served as steatosis. In the experimental group fell one head with a diagnosis of gastroenteritis.

4. The results of biochemical analysis of blood serum of pigs when used for prof the prevention of laboratory pigs and antihepatotoxic serum
IndexGroups of animals
group 1group 2
Total protein, g/l75,00,9of 87.84,0*
Albumin, %33,280,8941,531,63*
Alpha-globulins, %18,770,7816,340,41
Beta-globulins, %15,110,8511,950,75**
Gamma-globulins, %32,850,6130,181,25
The ratio A/G0,50,7
* - p<0,05, ** - p<0,01

When studying the content of total protein and protein fractions in the serum of experimental animals the increase of total protein content in the experimental group relative to the control 17.1% (p<0,01). Also in the experimental group, compared to controls, increased concentrations of albumins. Their number increased by +24,8% (p<0,01). In the experimental group occurred reliable reduced the e content of beta-globulin by 20.9%. The content in the serum gamma-globulin in the experimental group decreased compared with the control. This decrease was 8.1%. The ratio of albumin to globulins, which determines the functional state of the liver in the experimental group was higher than in the control at 40% and were within the normal range in contrast to the control.

These changes say about the strengthening of the protein-synthesizing function of the liver, increasing its metabolic activity and reduce the risk of hepatosis.

Tool for the prevention of hepatosis in pigs injected pigs at a dose of 0.2 ml/kg body weight subcutaneously or intramuscularly.

The remedy for the prevention of laboratory pigs is a clear liquid with a slight precipitate, easily broken during the shaking. The shelf life when stored at the temperature +5 - +7C 2 years.

Economic efficiency from the use of means for the prevention of laboratory pigs was 3.5 rubles, antihepatotoxic serum 0.8 ruble.

Sources of information

1. Abramov S. Effect of sodium hypochlorite on the normalization of biochemical parameters of blood of piglets suffering from gastroenteritis / Pub, Via // non-Communicable diseases in animals: Mater. int. scient. proc. - Kazan, 2000. - P.60-62.

2. Giants C.C. of Sodium hypochlorite and enterosorbent SV-1At toxic hepatobilary piglets / Vol, Car // Veterinary Medicine. - 2000. No. 12. - P.45-47.

3. Action-specific cytotoxic sera on the sex gland / Wasbasically, Nvironme, Lieberth, Ovision, Themselvesa, Asgenerally. - K.: Naukova Dumka, 1977. - 216 C.

4. Kudryavtsev A.P. Experience the elimination of toxic dystrophy of the liver of piglets at the farm "Lenin" / Prevention of diseases of farm animals. Parasitic and non-infectious diseases: Sat. scient. works Subnavi, vyp. - Omsk, 1976. - P.172-177.

5. Kuznetsov N. The effectiveness of lipemia when steatosis young pigs / Nkometou, Teleserve, Alilaguna, Ecbatane // Pig. - 2003. No. 4. - P.24.

6. Kuznetsov N. Prevention hepatosis in piglets / Niyazmatov, Vmmserver, Srilekhini // veterinary medicine. - 1999. No. 4. - P.37.

The remedy for the prevention of laboratory pigs containing antihepatotoxic serum, characterized in that it further comprises antiperoxidase serum and leukocyte plasma in the following ratio of components:

antihepatotoxic serumfrom 0.9 to 1.15 tetrofosmin units
antiperoxidase serumfrom 0.9 to 1.15 tetrofosmin units
lenoci the ary plasma 90-110 embryonic units
activity
phenolof 0.004-0.005 mg
salineto 1 ml



 

Same patents:

FIELD: chemistry.

SUBSTANCE: invention relates to novel compounds of general formula (I) , where the dotted line is either absent or denotes a double bond; R1 denotes H or C1-6-alkyl, possibly substituted with a CN group, or denotes a phenyl or sulphonyl phenyl, substituted with one or more B groups, or denotes -(CH2)m-Ra, where Ra denotes: NRiRii, C3-6-cycloalkyl, 6-member heterocycloalkyl, which denotes a univalent saturated group which contains one nitrogen heteroatom, the rest are carbon atoms, aryl, which can be substituted with one or more B groups, or denotes -(CH2)n-(CO)-Rb or -(CH2)n-(SO2)-Rb, where Rb denotes: NRiRii, 5-6-member heterocycloalkyl, which denotes a univalent saturated group containing one or more heteroatoms selected from nitrogen, oxygen, the rest are carbon atoms, aryl or 5- or 6-member heteroaryl, which denotes an aromatic ring containing two heteroatoms as ring members, the said heteroatoms selected from N or O, the rest are carbon atoms; which can possibly be substituted with one or more B groups, R2 denotes one or more H, halo, C1-6-alkyl, C1-6-alkoxy, R3 denotes H or-(CO)-Rc, where Rc denotes: C1-6-alkyl, 5-member heterocycloalkyl, which denotes a univalent saturated group containing one nitrogen heteroatom, the rest are carbon atoms possibly substituted with C1-6-alkyl, or denotes C1-6-alkyl; R4 denotes H; R5 denotes H, C1-6-alkyl, -(CH2)m-NRiRii, -(CH2)n-(CO)-Rb, where Rb denotes NRiRii or a 6-member heterocycloalkyl which denotes a univalent saturated group which contains one nitrogen heteroatom, the rest are carbon atoms, when the dotted line is absent or is absent when the dotted line denotes a double bond; R6 is absent, when the dotted line denotes a double bond; R7 denotes Cl or NReRf, where Re and Rf denotes H or C1-6-alkyl, or Re and Rf together with the nitrogen atom to which they are bonded form a 6-member heterocycloalkyl which denotes a univalent saturated group containing one or two heteroatoms selected from nitrogen, oxygen, the rest are carbon atoms; which can be substituted with C1-6-alkyl, or R6 and R7 together form a C=O group, when the dotted line is absent; B denotes halogen, C1-6-alkoxy, (CRiiiRiv)n-phenyl; Ri and Rii denote H, C1-6-alkyl -C(O)-C1-6-alkyl; Riii and Riv denote C1-6-alkyl; m equals to 1 or 2, n equals 0 or 1; as well as to pharmaceutically acceptable salts thereof. The invention also relates to a pharmaceutical composition, as well as to use of compounds of formula (I), (I-a) or (1-b).

EFFECT: obtaining novel biologically active compounds having activity on V1a receptor.

12 cl, 48 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to new oxoazepanylacetamide and oxoazepanylphenoxyacetamide derivatives, or to their stereoisomers or pharmaceutically acceptable salts described by general formula I where Q means O, S or N(R25); R25 means H; R80 is C6arylC1-4alkyl substituted by one or two substituted independently chosen from R3 groups; each R3 is independently chosen from a group including C1-4alkyl, C1-4alkoxy group, C2-6alkenyloxy group, halogen, C6aryloxy group, N(R20)(R21), R50, heteroaryl chosen from pyridine and thiazol where each alkoxy group and heteroaryl has optionally up to three substitutes independently chosen from R61 groups; and alkyl has optionally three substitutes independently chosen from R60 groups; or two R3 groups when they are present on carbon neighbours, together can form a fragment of formula -(O)a-(CH2)b-(O)c-(CH2)d-(O)e- where a, c and e independently mean 0 or 1, and both b and d independently mean 0, 1, 2 or 3; provided the fragment does not contain two oxygen neighbors and summed a, b, c, d and e are equal to 3 at least; R1 is chosen from a group including H, C1-4alkyl, C6arylC1-4alkyl; each R60 independently is chosen from a group including C1-C6a alkoxy group, NR12R13, halogen, heterocycloalkyl, such as piperidine; each R61 independently is chosen from a group including R60 and C1-C6alkyl; X means a group of formula -(CH2)n- where n means 2 or 3; or a group of formula II where Y means CH2, S; R75 and R76 means H; Z means C6aryl or heteroaryl, such as pyridine; each of which has optionally one substitutes chosen from R2 groups; R2 is chosen from a group including H, C1-4alkyl, halogen, heterocycloalkylC1-4alkyl, C6arylC1-4alkylaminoC1-4alkyl and a group of formula -(CH2)fN(R11)-(R10); where each heterocycloalkyl, arylalkylaminoalkyl has oprtionally one substitute chosen from R61 groups; f means 1; R11 means H; R10 means C1-6alkyl, C2-6alkenyl, C3-8cycloalkyl, aryl, C6arylC1-4alkyl, heteroarylC1-4alkyl where aryl has optionally one substitute chosen from R61 groups; each R12 and R13 independently mean C1-4alkyl; each R20 and R21 independently mean C1-4alkyl where alkyl has optionally one substitute chosen from R60 groups; and provided that the compound does not represent N-(4-ethoxybenzyl)-N-(2-oxoazepane-2-yl)-2-phenoxyacetamide or N-[(2-fluorophenyl)methyl]-N-(2- oxoazepane-3-yl)-2,2-diphenylacetamide. Also, the invention refers to a pharmaceutical composition of the compound of formula I, to methods of treating HCV viral infection and methods of relieving the symptoms of HCV viral infection with using the compound of formula I.

EFFECT: there are produced new oxoazepanylacetamide and oxoazepanylphenoxyacetamide derivatives showing HCV replication inhibiting activity.

1 tbl, 9 ex

FIELD: chemistry.

SUBSTANCE: invention relates to novel compounds of formula (I), where R2 denotes H, [(C1-C6) alkylene]0-1-R'; R3 denotes H; R4 denotes H, halogen or (C1-C6) alkyl; R5 denotes H or halogen; R6 denotes H, (C1-C8) alkyl, R', (C1-C6) alkylene-R'; R7 and R8 independently denote H, halogen, (C1-C6) alkyl, O-(C1-C6) alkyl, R'; R9 denotes (C1-C6)alkyl; n equals 0 or 1; L denotes O or O-(C1-C6)alkylene; where R' denotes (C3-C8) cycloalkyl; (C5-C10)heterocyclyl, which denotes an aromatic or saturated mono- or bicyclic ring system which, besides a carbon atom, includes one or more heteroatoms such as nitrogen, oxygen and sulphur atoms; or (C6-C10) aryl; where in the heterocyclyl is unsubstituted or substituted with (C1-C6)alkyl, and the aryl is unsubstituted or substituted with a halogen, (C1-C4)alkyl, -O-(C1-C4)alkyl, SO2- (C1-C4) alkyl or N[(C1-C4) alkyl]2; and where in groups R4, R6 and R7 the alkyl can be halogenised in one or more positions; or pharmaceutically acceptable salts and/or stereo isomer forms thereof. The invention also relates to use of formula (I) compounds, as well as a medicinal agent.

EFFECT: obtaining novel biologically active compounds having Rho-kinase inhibiting activity.

21 cl, 320 ex, 3 tbl

FIELD: medicine, veterinary science.

SUBSTANCE: invention refers to veterinary science, namely to therapy of internal nontransmitting diseases, particularly to drugs for chicken hepatosis prevention. The agent for chicken hepatosis prevention contains the ingredients in the following relation: antihepatotoxic serum 0.9-1.15 titre units; antisplenotoxic serum 0.9-1.15 titre units; phenol 0.004-0.005 mg; physiological solution up to 1 ml. The agent is introduced to chickens and chicks in dose 0.2 ml/kg of body weight subcutaneously or intramuscularly.

EFFECT: invention allows higher effectiveness of chicken hepatosis prevention.

4 tbl

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to hepatology, and can be applied in treatment of chronic hepatitis, caused by TTV virus. Method consists in simultaneous application of medication Amixin 0.125 in dose 1 pill every second day during 3 months in combination with medication fosfogliv in dose 2 pills 3 times per day during 3 months, with simultaneous treatment of sex partner.

EFFECT: application of invention allows to reach eradication of TTV form patient's organism with reduction of treatment time and reduction of complication quantity.

1 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to pharmacology and cell technologies. Medication, possessing regenerative activity, represents granulocytic colony-stimulating factor, immobilised on water-soluble polymers with molecular weight 400-4000 Da. Granulocytic colony-stimulating factor is immobilised on water-soluble polymers by means of ionising radiation - flow of accelerated electrons with energy 2.5 MeV, absorbed dose from 2 to 10 kGy and rate of dose gain 1.65 kGy/hour.

EFFECT: medication by claimed invention does not have immunogenicity, is highly efficient both in parenteral and peroral introduction.

10 tbl, 10 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, namely to pharmacology. An agent represents an aqueous solution of molecularly capsulated dihydroquercetin in the form of a water-soluble associate. Dihydroquercetin is homogenised in a melted surfactant or in a general solvent ethanol in the relation of the surfactant to dihydroquercetin 5:1 in a temperature range 40-70C to be mixed with water and concentrated by water evaporation.

EFFECT: invention allows higher bioavailability and activity of the agent, simplified technology.

4 cl, 3 ex, 3 tbl, 8 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmaceutical industry, in particular to hepatoprotective medication. Medication, which has hepatoprotective action, represents product of extraction by ethanol of thalli of Cha-Kombu - Laminaria japonica Aresch., of laminarian family -Laminariaceae, which contains to 30 % of polyphenol compounds.

EFFECT: medication possesses efficient hepatoprotective action, favours accelerated restoration of metabolic reactions cascade, ensuring normalisation of biochemical characteristics of carbon and lipid exchange, as well as endogenous antioxidant protection system.

6 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medicine, particularly to abdominal surgery, and is intended for purulent cholangitis treatment. The method includes draining and flushing of common bile duct with antiseptic agent. Miramistin solution is used as such agent, which is injected into common bile duct 2-3 times a day during 3-10 days.

EFFECT: invention enables to avoid adverse cytotoxic effect on tissues of hepatobiliary system, improve efficiency of local antibiotic treatment of cholangitis, including due to increased sensitivity of cholangitis germs to endogenous antimicrobial peptide protein.

2 ex, 3 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to drugs and concerns the application of CB1 receptor antagonist representing N-piperidino-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxamide or one of its pharmaceutically acceptable salts in preparing a composition for treating hepatic fibroses. Also the method of treating hepatic fibroses in mammals is disclosed.

EFFECT: invention aims at preparation of a drug for treating hepatic fibrosis.

13 cl, 4 dwg, 3 tbl, 6 ex

FIELD: medicine.

SUBSTANCE: claimed invention relates to medicine, namely, to psychiatry, and deals with treatment of schizophrenia. For this purpose in addition to adequate psychotropic therapy introduced is anapherone in dose 2 pills 4 times per day after equal time intervals independently on food intake for 25-35 days. Such complex treatment, including introduction of anapherone immune-modulator in developed regime and doses, ensures positive dynamics in immunity system, as well as improvement of clinical indices, which are registered by PANSS, AIMS and CGI scales.

EFFECT: method ensures positive dynamics in immunity system, as well as improvement of clinical indices.

7 tbl, 1ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine and pharmaceutical industry, namely to a composition containing acetocyclopropyl-taxotere and Trastuzumab used for treating breast cancer, for treating taxoid resistant cancer types.

EFFECT: preparation of the pharmaceutical composition for treating breast cancer.

2 cl, 1 tbl

FIELD: medicine, veterinary science.

SUBSTANCE: invention refers to veterinary science, namely to therapy of internal nontransmitting diseases, particularly to drugs for chicken hepatosis prevention. The agent for chicken hepatosis prevention contains the ingredients in the following relation: antihepatotoxic serum 0.9-1.15 titre units; antisplenotoxic serum 0.9-1.15 titre units; phenol 0.004-0.005 mg; physiological solution up to 1 ml. The agent is introduced to chickens and chicks in dose 0.2 ml/kg of body weight subcutaneously or intramuscularly.

EFFECT: invention allows higher effectiveness of chicken hepatosis prevention.

4 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: in invention described is hybridoma, producing monoclonal antibodies, which bind with protein 161P2F10B in a specific way. Invention describes versions of monoclonal antibodies, one of which includes amino acid sequence of heavy and light chain of antibody, produced by said hybridoma, and the other includes amono acid sequence of variable part of heavy and light chain of antibody, produced by said hybridoma, or amino acid sequence Fab, F(ab')2, Fv or Sfv of antibody fragment, which binds with protein 161P2F10B, 161P2F10B demonstrates tissue-specific expression in healthy, mature tissue and is abnormally expressed in case of oncologic diseases.

EFFECT: antibodies can be used as anti-cancer medication and in composition of pharmaceutical composition for treating cancer, in particular, kidney cancer, reducing tumour growth, as well as for detection of protein 161P2F10B in biological sample.

11 cl, 212 dwg, 8 tbl, 20 ex

FIELD: medicine, veterinary science.

SUBSTANCE: invention refers to veterinary science. A method involves hyperimmunisation of rabbits with an antigen with scheduled introduction of the immune-stimulating agent levamizole in the first and fourth day of hyperimmunisation, dynamic studying of antibody synthesis on the 7th, 14th, 21st and 30th days, exsanguination of the rabbits and production of serum. Antigen is vaccine strain C.burnetii M-44 inactivated by heating +70 for 30 minutes.

EFFECT: method allows producing Q fever serum with a high diagnostic antibody titres, as well as increasing diagnostic accuracy in bovine Q fever.

5 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to biotechnology. Antibodies have been constructed by substitution of one or several amino acids of parent antibody with highly reactive cysteine amino acid residues, which are not crosslinked. Described antibodies have been conjugates with one or several molecules of drug (D) by means of linker (L), which resulted in obtaining conjugates of formula: Ab-(L-D)P, where p equals 1-4. Also described is diagnostic and therapeutic application of compounds in pharmaceutical compositions.

EFFECT: invention can be used for aims of in vitro, in situ and in vivo diagnostics or for processing of mammalian cells or treatment of associated with them pathological conditions.

51 cl, 25 dwg, 7 tbl, 12 ex

FIELD: medicine.

SUBSTANCE: invention relates to field of medicine. Invention describes application of remyelinating medication for obtaining medication in amount, stimulating remyelination of nerve cells in mammals, for treatment of demyelinating disease and method of stimulating remyelination of nerve cells in mammals, where medication is introduced to constantly demanding it mammal; constant introduction of remyelinating medication represents weekly or monthly introduction during period, equal to, at least, six months; and remyelinating medication represents antibody or its immunologically active enzyme, binding with alfa-4-integrin, and, in particular, antibody represents monoclonal antibody natalizumab or its immunologically active fragment.

EFFECT: application of remyelinating medication for obtaining medication in amount, stimulating remyelination of nerve cells in mammals.

26 cl, 20 tbl, 18 dwg, 381 ex

FIELD: medicine.

SUBSTANCE: by means of expression vector into plant cell introduced are nucleotide sequences, coding light and heavy chains of antibody, binding human VEGF. Antibody against human VEGF can be used, in particular, for reduction of microvascular permeability of human tumours and treatment of diabetic and age-related neovascular retinopathy.

EFFECT: antibody production in plant cells provides possibility of its obtaining in industrial scale, at a significantly lower cost than in obtaining in expression system on mammalian cell culture base, presence in obtained preparation of antibody of causative agents of prion, mycoplasmal and viral diseases of mammals is excluded.

39 cl, 11 dwg, 2 ex

FIELD: medicine.

SUBSTANCE: claimed are versions of separated monoclonal antibody, specific to INNAR-1. Described are: bispecific molecule, immunoconjugate and compositions for treatment of IFNAR-1-mediated diseases and disorders based on monoclonal antibody. Also described are methods of inhibiting biological activity of type I interferons, method of treating diseases and disorders, mediated by type I interferon with application of antibody. Claimed are nucleic acid, which codes antibody, vector for antibody expression, cell, transformed by vector, as well as method of obtaining antibodies and antibody-producing hybridoma.

EFFECT: application of invention provides novel IFNAR-1 inhibiting antibodies, which block IFNAR-1 and bind its other epitope, in comparison with known antibody 64G12.

29 cl, 15 dwg, 6 tbl, 9 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, oncology, and can be used for photodynamic tumour treatment. For this purpose photosensitiser (PS) of chlorine line is introduced intravenously by drop infusion during 10 minutes in dose 0.8 mg/kg of body weight. 10 minutes after finishing PS introduction, retina is irradiated transpupillarly by laser radiation with wavelength corresponding to maximum of absorption of light radiation by PS with energy density 40-50 J/cm2. Irradiation is performed concentrically from zone of vascular arcades to utmost periphery by fields with 4 mm diametre with covering 5% of area of adjacent fields. Next day preparation ranimizumab is introduced to patient intravitreally in dose 0.5 mg.

EFFECT: method allows to provide impediment for development of neovascularisation of eye anterior segment with complete organic blockade of anterior chamber angle and further intraocular pressure decompensation, reduces risk of development of inflammatory complications after laser impact on retina.

FIELD: genetic engineering, immunology, medicine.

SUBSTANCE: invention relates to new antibodies directed against antigenic complex CD3 and can be used in therapeutic aims. Antibody IgG elicits the affinity binding with respect to antigenic complex CD3 wherein heavy chain comprises skeleton of the human variable region in common with at least one CD3 taken among amino acid sequences SEQ ID NO 2, 4 and 6 and their corresponding conservatively modified variants. Light chain comprises skeleton of the rodent variable region in common with at least one CD3 taken among amino acid sequences SEQ ID NO 8, 10 and 12 and their corresponding conservatively modified variants. Antibody is prepared by culturing procaryotic or eucaryotic cell co-transformed with vector comprising recombinant nucleic acid that encodes antibody light chain and vector comprising recombinant nucleic acid that encodes antibody heavy chain. Antibody is administrated in the patient suffering with malignant tumor or needing in immunosuppression in the effective dose. Invention provides preparing chimeric antibodies against CD3 that are produced by expression systems of procaryotic and eucaryotic cells with the enhanced yield.

EFFECT: improved preparing methods, valuable medicinal properties of antibody.

33 cl, 5 dwg, 1 ex

Up!